NANONERVE, INC. — Department of Health and Human Services SBIR Phase II: NINDS
NANONERVE, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,351,152
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NINDS
- Solicitation
- PA12-088
- NAICS
- —
- Place of performance
- CA
- Period
- 2013-09-16 → 2016-08-31
Description
<p>DESCRIPTION provided by applicant NanoNerve is developing a novel diametrically patterned nanofibrous dural substitute for rapid dura mater regeneration following neurosurgical procedures In the US alone neurosurgical procedures are performed annually that require patching of the dura mater to prevent leakage infection and neural damage Currently available dural substitutes include xenogenic collagen matrices and permanent synthetic devices Xenogeneic collagen matrices have significant disadvantages including low mechanical strength low suturability and high cost and disease transmission risks The permanent synthetic devices also suffer from major disadvantages including resistance to dura mater regeneration need for extensive suturing during implantation and higher leakage rates The overall goal of the project is FDA K clearance and commercialization of a highly versatile diametrically patterned nanofibrous dural substitute NanoNerve is utilizing its patent pending electrospinning technology to diametrically pattern nanofibers for rapidly regenerating dural tissue from the entire periphery of the defect toward the center NanoNerveandapos s synthetic bioresorbable nanofibrous dural substituteandapos s ultra thin profile and high mechanical strength will enable it to become the first synthetic dural substitute capable of sutured and suture free implantation This Phase II project will continue development of the diametrically patterned nanofibrous dural substitute by performing biocompatibility safety stability and long term in viv implantation studies Upon achievement of Phase II milestones NanoNerve will file an FDA IDE application for human clinical testing and eventually an FDA k for market clearance PUBLIC HEALTH RELEVANCE Over neurosurgical procedures are performed annually that require grafting of the dura mater to prevent fluid leakage infection and neural tissue damage Currently available dural substitutes have major limitations including incomplete dural repair low mechanical strength and high leakage rate complications This phase II study will enable development of a strong versatile and diametrically patterned nanofibrous dural substitute for rapid and effective dura mater regeneration</p>